I-lab2018 Bpifrance

Jul 23, 2018

Exeliom Biosciences is awarded I-Lab2018 from Bpifrance

#biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics

Oct 19, 2023

Exeliom Biosciences Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 1 Clinical Trial of EXL01 in Crohn’s Disease

Apr 27, 2023

SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism

Nextbiotix Exeliom Biosciences

Feb 15, 2019

Nextbiotix becomes Exeliom Biosciences

contact

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.